Skip to content

Inspection Record

Qingdao Kangyuan Pharmaceutical Co., LTD — FDA 483 Findings

US FDAInspected 2013-01-25Published 2026-11-13 6 findingsOther quality systemEquipment and facilityLaboratory and QC controls

Inspectors Jose R. HernandezThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

SOP 09-301 requires analytical balances to be placed on a vibration proof surface.

2Other quality system

The BPR does not document the duration of the, _—step of the 4) 4 during production; for example, at | | ?

4Other quality system

The pw step requires the use of oa i apparatus).

5Laboratory and QC controls

The contract laboratory performs the residual solvent test for detectinga@ in the finished product.

6Other quality system

There was no study protocol to for developing an impurity profile on the product nor there was an impurity profile on@@ for review.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Qingdao Kangyuan Pharmaceutical Co., LTD findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.